Financial Ratios BriaCell Therapeutics Corp.
Stocks
BCT
CA1079303071
Biotechnology & Medical Research
|
Market Closed -
Toronto S.E.
15:59:56 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 5.040 CAD | +1.00% |
|
+2.23% | -48.57% |
| Fiscal Period: July | 2016 (CAD) | 2017 (CAD) | 2018 (CAD) | 2019 (CAD) | 2020 (CAD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -14.88 | -18.99 | -41.71 | -126.11 | -123.56 | |||||
Return on Total Capital | -16.11 | -50.26 | -444.01 | 644.72 | -232.14 | |||||
Return On Equity % | -1.6 | -141.25 | -619.75 | 152.63 | -362.56 | |||||
Return on Common Equity | -1.6 | -141.25 | -619.75 | 155.58 | -339.54 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 103.81 | 45 | 14.96 | 0.49 | 5.01 | |||||
Quick Ratio | 102.88 | 43.64 | 11.81 | 0.21 | 4.49 | |||||
Operating Cash Flow to Current Liabilities | -13.91 | -13.27 | -13.18 | -3.23 | -7.08 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 0.05 | - | - | - | - | |||||
Total Debt / Total Capital | 0.05 | - | - | - | - | |||||
LT Debt/Equity | 0.05 | - | - | - | - | |||||
Long-Term Debt / Total Capital | 0.05 | - | - | - | - | |||||
Total Liabilities / Total Assets | 1.35 | 75.74 | 113.91 | 145.72 | 19.93 | |||||
EBIT / Interest Expense | -151.29 | -15.62K | - | - | -735.68 | |||||
EBITDA / Interest Expense | -150.95 | -15.6K | - | - | -732.8 | |||||
(EBITDA - Capex) / Interest Expense | -150.95 | -15.6K | - | - | -732.8 | |||||
Total Debt / EBITDA | -0 | - | - | - | - | |||||
Net Debt / EBITDA | 8.23 | 2.69 | 0.91 | 0.03 | 0.66 | |||||
Total Debt / (EBITDA - Capex) | -0 | - | - | - | - | |||||
Net Debt / (EBITDA - Capex) | 8.23 | 2.69 | 0.91 | 0.03 | 0.66 | |||||
Growth Over Prior Year | ||||||||||
EBITDA, 1 Yr. Growth % | 77.32 | 119.42 | 52.27 | 42.95 | -18.49 | |||||
EBITA, 1 Yr. Growth % | 77.32 | 119.42 | 52.27 | 43.25 | -18.39 | |||||
EBIT, 1 Yr. Growth % | 77.02 | 119.16 | 52.22 | 43.22 | -18.38 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -89.36 | 94.26 | -24.35 | -75.71 | 438.5 | |||||
Net Income, 1 Yr. Growth % | -89.36 | 94.26 | -24.35 | -76.4 | 449.14 | |||||
Normalized Net Income, 1 Yr. Growth % | -94.26 | 96.27 | -24.35 | -76.81 | 457.03 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | - | -43.34 | -24.96 | -77.6 | 42.37 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | - | - | - | - | -23.53 | |||||
Total Assets, 1 Yr. Growth % | 11.01K | -26.65 | -36.2 | -78.38 | 268.68 | |||||
Tangible Book Value, 1 Yr. Growth % | -1.58K | -63.18 | -139.53 | -35.32 | -785.32 | |||||
Common Equity, 1 Yr. Growth % | -1.69K | -62.67 | -136.57 | -36.93 | -850.54 | |||||
Cash From Operations, 1 Yr. Growth % | 512.03 | 61.08 | 90.2 | 1.61 | 16.76 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -2.87K | 17.57 | 131.39 | -31.72 | 74.39 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -2.64K | 18.56 | 131.41 | -31.72 | 74.17 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
EBITDA, 2 Yr. CAGR % | 17.39 | 97.29 | 82.79 | 47.54 | 7.94 | |||||
EBITA, 2 Yr. CAGR % | 17.39 | 97.29 | 82.79 | 47.69 | 8.12 | |||||
EBIT, 2 Yr. CAGR % | 17.34 | 97 | 82.65 | 47.65 | 8.12 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -69.85 | 158.24 | 21.22 | -57.13 | 14.37 | |||||
Net Income, 2 Yr. CAGR % | -69.85 | 158.24 | 21.22 | -57.75 | 13.84 | |||||
Normalized Net Income, 2 Yr. CAGR % | -78.8 | 160.33 | 21.85 | -58.12 | 13.65 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | -34.79 | -59 | -43.52 | |||||
Total Assets, 2 Yr. CAGR % | 1.04K | 802.85 | -31.59 | -62.86 | -10.72 | |||||
Tangible Book Value, 2 Yr. CAGR % | 668.75 | 61.78 | -61.85 | -49.43 | 110.54 | |||||
Common Equity, 2 Yr. CAGR % | 811.86 | 69.45 | -63.05 | -51.97 | 117.58 | |||||
Cash From Operations, 2 Yr. CAGR % | 36.68 | 214.04 | 75.04 | 39.01 | 8.92 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 55.87 | 470.27 | 64.94 | 25.7 | 9.12 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 56.01 | 446.85 | 65.64 | 25.7 | 9.05 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
EBITDA, 3 Yr. CAGR % | 20.5 | 44.62 | 80.97 | 68.41 | 21.06 | |||||
EBITA, 3 Yr. CAGR % | 20.5 | 44.62 | 80.97 | 68.52 | 21.2 | |||||
EBIT, 3 Yr. CAGR % | 20.45 | 44.52 | 80.77 | 68.43 | 21.18 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -53.79 | 78.58 | 71.51 | -29.06 | -0.35 | |||||
Net Income, 3 Yr. CAGR % | -53.79 | 78.58 | 71.51 | -29.74 | -0.66 | |||||
Normalized Net Income, 3 Yr. CAGR % | -61.6 | 74.45 | 72.43 | -29.92 | -0.77 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | -54.33 | -37.91 | |||||
Total Assets, 3 Yr. CAGR % | 189.7 | 357.49 | 273.26 | -53.4 | -20.18 | |||||
Tangible Book Value, 3 Yr. CAGR % | 333.41 | 118.75 | 1.14 | -54.51 | 20.56 | |||||
Common Equity, 3 Yr. CAGR % | 287.08 | 146.61 | 1.64 | -55.84 | 20.07 | |||||
Cash From Operations, 3 Yr. CAGR % | 24.9 | 44.39 | 165.7 | 46.01 | 31.16 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 26.63 | 41.75 | 322.19 | 22.93 | 40.19 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 26.57 | 42.06 | 310.56 | 23.27 | 40.14 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
EBITDA, 5 Yr. CAGR % | 31.87 | 43.49 | 43.89 | 45.78 | 47.18 | |||||
EBITA, 5 Yr. CAGR % | 31.86 | 43.49 | 43.89 | 45.84 | 47.28 | |||||
EBIT, 5 Yr. CAGR % | 31.91 | 43.52 | 43.81 | 45.76 | 47.18 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -24.76 | 60.59 | 37.61 | 0.91 | 45.84 | |||||
Net Income, 5 Yr. CAGR % | -24.76 | 60.59 | 37.61 | 0.33 | 45.58 | |||||
Normalized Net Income, 5 Yr. CAGR % | -33.55 | 60.59 | 39.78 | -1.42 | 45.95 | |||||
Total Assets, 5 Yr. CAGR % | 131.37 | 92.97 | 64.38 | 67.55 | 110.62 | |||||
Tangible Book Value, 5 Yr. CAGR % | 133.33 | 69.14 | 43.16 | 21.76 | 35.61 | |||||
Common Equity, 5 Yr. CAGR % | 133.53 | 69.9 | 32.18 | 28.17 | 37.81 | |||||
Cash From Operations, 5 Yr. CAGR % | 43.89 | 52.92 | 44.5 | 42.22 | 85.99 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 56.86 | 65.67 | 42.18 | 35.1 | 145.73 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 56.7 | 65.67 | 42.28 | 35.27 | 141.59 |
- Stock Market
- Stocks
- BCT Stock
- Financials BriaCell Therapeutics Corp.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















